DDInter1293 DDInter1676
Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to treatment with imatinib (Gleevec), another tyrosine kinase inhibitor used as a first-line treatment for CML.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Nilotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ponatinib
Nilotinib {u} (Compound) treats {v} (Disease) hematologic cancer
Nilotinib {u} (Compound) binds {v} (Gene) CA7
Nilotinib {u} (Compound) upregulates {v} (Gene) HERPUD1
Nilotinib {u} (Compound) is included by {v} (Pharmacologic Class) Protein Kinase Inhibitors
Nilotinib {u} (Compound) downregulates {v} (Gene) BNIP3
Nilotinib {u} (Compound) causes {v} (Side Effect) Lymphopenia
Nilotinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Raltegravir
Nilotinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sulfamethoxazole
Nilotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Methysergide
Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib
Nilotinib (Compound) treats hematologic cancer (Disease)
Nilotinib (Compound) binds CA7 (Gene)
Nilotinib (Compound) upregulates HERPUD1 (Gene)
Nilotinib (Compound) is included by Protein Kinase Inhibitors (Pharmacologic Class)
Nilotinib (Compound) downregulates BNIP3 (Gene)
Nilotinib (Compound) causes Lymphopenia (Side Effect)
Nilotinib may cause a minor interaction that can limit clinical effects when taken with Raltegravir
Nilotinib may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole
Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Methysergide